Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share (the "Shares")
-
Shares outstanding
-
31,306,673
-
Total 13F shares
-
15,126,531
-
Share change
-
-89,651
-
Total reported value
-
$196,038,266
-
Price per share
-
$12.96
-
Number of holders
-
40
-
Value change
-
-$1,147,223
-
Number of buys
-
22
-
Number of sells
-
15
Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) as of Q2 2023
As of 30 Jun 2023,
Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (the "Shares") (ACRV) was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,126,531 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Sands Capital Ventures, LLC, CITADEL ADVISORS LLC, WELLINGTON MANAGEMENT GROUP LLP, MARSHALL WACE, LLP, BlackRock Inc., NEA Management Company, LLC, VANGUARD GROUP INC, and FEDERATED HERMES, INC..
This page lists
40
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.